Anti-CD30 / TNFRSF8 (Hodgkin & Reed-Sternberg Cell Marker) Polyklonale Antilichaam

Recognizes a single chain glycoprotein of 105/120kDa, identified as CD30/Ki-1. CD30 is synthesized as a 90kDa precursor, which is processed in the Golgi complex into a membrane-bound phosphorylated mature 105/120kDa glycoprotein. In Hodgkin's disease, CD30/Ki-1 antigen is expressed by mononuclear-Hodgkin and multinucleated Reed-Sternberg cells. It is also expressed by the tumor cells of a majority of anaplastic large cell lymphomas as well as by a varying proportion of activated T and B cells. This antibody distinguishes large cell lymphomas derived from activated lymphoid cells from histiocytic malignancies and lymphomas derived from resting and precursor lymphoid cells or from anaplastic carcinomas. About one third of the Ki-1 positive lymphomas lack the leukocyte common antigen (CD45) .

CD30L receptor, Cytokine receptor CD30, Ki-1 antigen, Lymphocyte activation antigen CD30, Tumor necrosis factor receptor superfamily member 8 (TNFRSF8)

TNFRSF8

943

P28908

Human

Recombinant human TNFRSF8 protein fragment

IHC

200 μg/mL of Ab Purified by Protein A Column. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/mL.

Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous.

Immunohistochemistry (Formalin-fixed) (1-2ug/ml for 30 minutes at RT) (Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 8.0, for 45 min at 95&degC followed by cooling at RT for 20 minutes)

Rabbit IgG